Margo Roberts
Directeur/Bestuurslid bij UNITY BIOTECHNOLOGY, INC.
Vermogen: - $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jeffrey Wiezorek | M | 52 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 jaar |
Nathaniel David | M | 56 | 15 jaar | |
Keith Leonard | M | 62 | 8 jaar | |
David Baltimore | M | 86 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 jaar |
Jeenjoo Kang | M | 40 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 jaar |
Lynne Sullivan | F | 58 | 4 jaar | |
Pin Wang | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 jaar |
Edmund Kim | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 jaar |
Lili Yang | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 jaar |
Stephen Hill | M | 53 | 5 jaar | |
Alexander Nguyen | M | 47 | 3 jaar | |
Michael Samar | M | 51 | 2 jaar | |
Gilmore O’Neill | M | 59 | 4 jaar | |
Anirvan Ghosh | M | 60 | 4 jaar | |
Dominic Piscitelli | M | 50 | 4 jaar | |
Camille Samuels | F | 52 | 9 jaar | |
David Georges | M | - | 5 jaar | |
William Rieflin | M | 64 | 4 jaar | |
Paul Berns | M | 57 | 6 jaar | |
James H. Wyckoff | M | 72 |
University of Virginia
| 16 jaar |
Daqing Cai | M | 59 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
David Moskowitz | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
Francisco Gimenez | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
Richard D. Goold | M | 64 | 5 jaar | |
Harry Harding | M | - |
University of Virginia
| 15 jaar |
Antonio Jose Periquet | M | 62 |
University of Virginia
| 13 jaar |
Carolyn S. Miles | F | 62 |
University of Virginia
| 15 jaar |
Elizabeth L. Anderson | M | 83 |
University of Virginia
| 19 jaar |
Przemyslaw Sapieha | M | - | 3 jaar | |
Chris McDonald | M | - | 6 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Arie Belldegrun | M | 74 | 8 jaar | |
Aya Jakobovits | M | 71 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 14 jaar |
Patrick Jeanmart | M | 51 | 11 jaar | |
Christian Homsy | M | 65 | 12 jaar | |
Filippo Petti | M | 52 | 4 jaar | |
David Tanen | M | 52 | - | |
Ferdinand Hui | M | - |
University of Virginia
| 8 jaar |
Paul L. Jenkinson | M | 64 | 1 jaar | |
Edward Shuman | M | - |
University of Virginia
| 9 jaar |
David Chang | M | 64 | 4 jaar | |
David Clark | M | 47 |
University of Virginia
| 5 jaar |
David Bonderman | M | 81 | 6 jaar | |
Francis Teo | M | - |
University of Virginia
| 6 jaar |
David Lacey | M | 71 | 2 jaar | |
Andrew Trees | M | - |
University of Virginia
| 4 jaar |
Erin McCormack | F | - |
University of Virginia
| 4 jaar |
Alexander T. Seals | M | - |
University of Virginia
| 5 jaar |
JJ Kasper | M | - |
University of Virginia
| 8 jaar |
Thomas Decarlo | M | - |
University of Virginia
| - |
Rachel C Cantor | F | - |
University of Virginia
| 4 jaar |
Kevin Matthew Mixon | M | - |
University of Virginia
| 4 jaar |
Howard Hechler | M | - |
University of Virginia
| 4 jaar |
Katie Bullard | F | - |
University of Virginia
| 4 jaar |
Austine Graff | F | - | 1 jaar | |
Maria Koehler | M | 67 | - | |
Ryan Berg | M | - |
University of Virginia
| 10 jaar |
Zachary Bratun Glennon | M | - |
University of Virginia
| 4 jaar |
Adam Fassnacht | M | - |
University of Virginia
| 6 jaar |
Altaf Bahora | M | - |
University of Virginia
| 12 jaar |
John Smalley | M | - |
University of Virginia
| 12 jaar |
Neil Carter | M | - |
University of Virginia
| 11 jaar |
Scott B Crenshaw | M | - |
University of Virginia
| 6 jaar |
Max Leykin | M | - |
University of Virginia
| 5 jaar |
McGavock Dickinson Dunbar | M | - |
University of Virginia
| 4 jaar |
Jonathan Chou | M | - |
University of Virginia
| 7 jaar |
Raju S. Kucherlapati | M | 81 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 jaar |
Robert Nelsen | M | 60 | 9 jaar | |
Craig S. Edwards | M | - |
University of Virginia
| 5 jaar |
Kristina Burow | F | 50 | 11 jaar | |
Franz Humer | M | 76 | 2 jaar | |
Farah Champsi | F | 62 | 4 jaar | |
Roy Doumani | M | 89 | 6 jaar | |
Cynthia Butitta | F | 70 | 4 jaar | |
R. Greer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 5 jaar |
Brian Nold | M | - |
University of Virginia
| 8 jaar |
Heather Turner | F | 51 | 4 jaar | |
Graham Cooper | M | 54 | 5 jaar | |
Ian Clark | M | 62 | - | |
Robin Washington | F | 60 | - | |
Joshua Kazam | M | 47 | 8 jaar | |
Stephen Sherwin | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 19 jaar |
Steven Ruchefsky | M | 61 | 6 jaar | |
Claudine Prowse | M | - | - | |
Kristina Wilmer | F | - |
University of Virginia
| 7 jaar |
Christine Cassiano | F | - | 1 jaar | |
Rahul Gorawara | M | - |
University of Virginia
| 5 jaar |
Jonathan Peacock | M | 66 | 3 jaar | |
Greg Mann | M | - | - | |
Larry L. Green | M | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | - |
Elizabeth Faust | M | 59 | 2 jaar | |
Ran Nussbaum | M | 51 | 4 jaar | |
Chris Carroll | M | - |
University of Virginia
| 4 jaar |
Timothy Moore | M | 62 | 3 jaar | |
Nitin Chandra | M | - |
University of Virginia
| 9 jaar |
Steven Koch | M | - |
University of Virginia
| 4 jaar |
Jonathan D. Gladden | M | - |
University of Virginia
| 2 jaar |
Jehangir Saifullah Khan | M | - |
University of Virginia
| 4 jaar |
Evan Cantor | M | - |
University of Virginia
| 4 jaar |
Mark Christopher Koontz | M | 45 |
University of Virginia
| 4 jaar |
Lee Daniel Miller | M | - |
University of Virginia
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 94 | 94.00% |
België | 6 | 6.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Margo Roberts
- Persoonlijk netwerk